BFRIHIGH SIGNALFINANCIAL10-K

BFRI shows dramatic improvement with stockholders' equity surging 136% to $10.5M while net losses narrowed significantly from -$17.8M to -$10.5M despite increased R&D spending.

The substantial equity increase and 41% reduction in net losses suggest either successful capital raising or major operational improvements that have strengthened the company's financial foundation. However, the 30% deterioration in operating cash flow to -$13.4M indicates the company is still burning cash at an accelerating rate, which could pressure the improved balance sheet position.

Comparing 2026-03-19 vs 2025-03-20View on EDGAR →
FINANCIAL ANALYSIS

BFRI demonstrates mixed but notable financial progress with revenue growing 12% to $41.7M and total assets expanding 29% to $28.6M, while dramatically improving profitability metrics including a 41% reduction in net losses. The company significantly boosted R&D investment by 78% to $3.7M and reduced inventory by 79%, suggesting a strategic shift toward development activities and improved working capital management. However, the 30% worsening in operating cash flow to -$13.4M outflow remains concerning despite the substantial 136% increase in stockholders' equity, indicating ongoing cash burn that could test the strengthened balance sheet.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+136.4%
$4.4M$10.5M

Equity base grew 136.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-80%
$10K$2K

Capex reduced 80% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
-78.5%
$6.6M$1.4M

Inventory drawn down 78.5% — strong sell-through or deliberate destocking; watch for supply constraints.

R&D Expense
P&L
+78%
$2.1M$3.7M

R&D investment increased 78% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
+40.7%
-$17.8M-$10.5M

Net income grew 40.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+34.1%
-$17.2M-$11.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
-30.1%
-$10.3M-$13.4M

Operating cash flow fell 30.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
+29.2%
$22.1M$28.6M

Asset base grew 29.2% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
-12.6%
$20.7M$18.1M

Current assets declined 12.6% — monitor working capital adequacy and short-term liquidity.

Revenue
P&L
+11.7%
$37.3M$41.7M

Revenue growing 11.7% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-20
ADDED
As of March 16, 2026, there were 11,648,323 shares outstanding of the registrant s common stock, par value $ 0.001 per share.
TRADEMARKS, TRADE NAMES, AND SERVICE MARKS All trademarks, trade names, and service marks appearing in this Form 10-K are the property of their respective owners.
Solely for convenience, the trademarks and trade names in this Form 10-K are referred to without the symbols and , but such references should not be construed as any indication that their respective owners will not assert their rights thereto to the fullest extent under applicable law.
We do not intend to use or display other companies trademarks, trade names, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Business Overview We are a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy ( PDT ).
+7 more — sign up free →
REMOVED
As of March 19, 2025, there were 8,873,932 shares outstanding of the registrant s common stock, par value $ 0.001 per share.
References in this Form 10-K to Ferrer refer to Ferrer Internacional S.A.
References in this Form 10-K to Licensors refer collectively to Biofrontera Pharma, Biofrontera Bioscience and Ferrer.
References in this Form 10-K to Ameluz Licensor refer collectively to Biofrontera Pharma and Biofrontera Bioscience.
Business Overview We are a United States based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy ( PDT ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →